In the multivariate model, which included the standard clinical and pathological factors significant in the univariate analysis, MRM, larger tumor size, lymph node involvement, and treated with tamoxifen and aromatase inhibitors continued to act as independent prognostic factors for BCSS events, whereas PgR positivity (HR, 0.374; 95% CI, 0.234–0.597; p < 0.001) acted as an independent protective factor for BCSS events. The gene discussed is CYP19A1; the disease is neoplasm.